May 2026 update

The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.

May 17, 2026 Monthly Update

I Believe FGF-1 is the Biggest Medical Breakthrough of the Last 84 Years.

Note: Brett Favre — Below in Vika's Patient Comments section, is a post from and a picture with Brett Favre, one of America's greatest football players. Brett has publicly shared his struggle with Parkinson's disease. He has been taking FGF-1 for three months and, in his post, reveals that he has reduced his other Parkinson's medication by 50%. He believes he is healing.

Brett, one of the best quarterbacks in football history and known for his competitive spirit, now faces the most important game of his life: his recovery from Parkinson's disease. On Brett's team are the 250 Parkinson's patients who cleared the path for him by using Zhittya's FGF-1 to demonstrate recovery from this disease.

I believe that for all his football victories and fame, his recovery from Parkinson's disease will be his greatest moment. I believe he will show millions of people that Parkinson's, strokes, dementia, Alzheimer's, multiple sclerosis, brain injuries, and more can be healed just like a broken arm is healed today. I believe Zhittya has been blessed by our new player to the team in this most important game: the game to recover from Parkinson's disease.

Go Brett, Go!!!

If you haven’t seen that post, see it here: https://x.com/BrettFavre/status/2053880774252757487

Introduction:

Zhittya now has over 150,000 people who receive our Monthly Updates. We have added about 50,000 new readers in the last four months. Many of these new readers, as well as others, do not yet understand what Zhittya is doing or why.

I receive criticism from biotech experts who tell me Zhittya is not following the traditional process of developing medicines. I agree with them. I will not follow a business development model with a 95% failure rate, and one that takes 20 years to get a medicine approved while denying safe treatments that could reduce pain and suffering for millions of people, as well as extend their lives.

It has been said, "Insanity is doing something you know will not work, hoping for a different outcome." Few people would disagree that the American system for developing new medicines is dysfunctional. A fierce debate is going on right now about the changes that are needed, including medicines that are safe and can enhance lives, but whose approvals have been stalled for decades—while unproven, untested medicines are being recommended to children.

Before the FDA bureaucracy existed, medicines were developed for hundreds of years, and people's health improved. I believe FGF-1 is the biggest medical breakthrough of the last 84 years, and it could treat the underlying cause of 65% of deaths and human suffering. Our plan to succeed is not to do what we believe does not work; it is to use common sense and apply what is actually needed to deliver these medical treatments to people as soon as possible.

A Historical Parallel: Penicillin

In the 1930s, the leading causes of sickness and death were bacterial diseases: tuberculosis, pneumonia, diphtheria, scarlet fever, typhoid fever, cholera, syphilis, and meningitis. Even a small wound could become infected and turn fatal. In 1942, the first person in the United States was treated with penicillin, and the battle against bacteria changed human life forever. Today, few of us die from bacterial infections. Few of us fear fatality from a small cut and resulting bacterial infection. Life expectancy increased by roughly 20 years. That medical breakthrough started 84 years ago, and it was a great thing for all of humanity.

In 2026, it is reported that 65% of all adult deaths in the world are caused by insufficient blood flow to a tissue or organ.

• Insufficient blood flow in the heart: causes an estimated 38% of all deaths worldwide.
• Insufficient blood flow in the brain: the 3rd leading cause of death at 14% worldwide.

Together, those two account for 52% of all deaths worldwide, and there are 70+ additional diseases also tied to insufficient blood flow at the cellular level. Many bacterial infections have different names; however, one medical treatment resolved them: antibacterial medicines. Today, I believe 65% of the diseases that kill people all have the same root problem: insufficient blood flow, and I believe the treatment is FGF-1.

FGF-1 was discovered at Washington University in St. Louis in the mid-1980s, over 40 years ago. Thousands of medical and scientific papers have been written about this natural miracle molecule, which can trigger new blood vessel growth, repair damaged blood vessels, rejuvenate cells in the brain, and more. To my knowledge, Zhittya is the only company working to make the FGF-1 medicine available to those tens of millions of people who suffer from a lack of blood flow to a tissue or organ. We have human data showing that in patients with severe heart disease, FGF-1 can enhance blood flow, lessen pain, and extend lives. We have dosed over 250 Parkinson's disease patients with outstanding results. We have human data on healing non-healing diabetic foot ulcers. We have human data on 85 type-2 diabetics showing FGF-1 can safely reverse their type-2 diabetes. And there are many more medical needs that I and others believe FGF-1 could treat.

An Example: Kidney Disease

For this update, I want to walk you through an example. I just did a Google search on: "Can FGF-1 treat kidney disease?"

The answer: Yes — FGF-1 is a powerful signaling protein that helps regulate tissue repair, cell growth, and metabolism. In preclinical studies on diabetic nephropathy (kidney disease caused by diabetes) and acute kidney injury, researchers have found that FGF-1 provides several benefits, including:

• Reduces inflammation: It actively lowers inflammatory markers and suppresses immune cell infiltration in kidney tissue.
• Decreases fibrosis: It helps prevent the buildup of scar tissue, protecting the delicate structures of the kidneys.
• Prevents cell death: It promotes the survival of renal tubular cells, which are vital for filtering waste.

And then this line: "Despite the promising results seen in animal and laboratory studies, there are significant hurdles to overcome before FGF-1 can be used as a standard cure for kidney disease in humans."

You can search for many diseases (except cancers) and ask, “Can FGF-1 treat XYZ?” Read the answers from the world's accumulated medical knowledge, and the answer is often yes; and yet, despite the promising results, FGF-1 has not been available for human use for the last 30 years.

FGF-1 has shown promise for over 30 years that it could treat diseases and extend lives. And people think Zhittya should quit because we refuse to proceed with a business model that I believe guarantees failure. Zhittya must use common business sense to succeed, not fail in an academic fantasy.

Zhittya is overwhelmed with diseases that FGF-1 can treat, all hitting that same wall: "Despite the promising results seen in animal and laboratory studies, there are significant hurdles to overcome before FGF-1 can be used as a standard cure." A Discovery in Progress: Type-1 Diabetes?

Zhittya has reviewed years of medical research papers on how FGF-1 in the brain could reverse type 2 diabetes. It is reported that 37 million Americans have diabetes. Zhittya has reviewed the animal data, which for 12 years has shown FGF-1 can safely reverse type 2 diabetes in animals. These studies were conducted by some of the leading medical research organizations in the world.

Zhittya witnessed in its Parkinson's disease patients 25 people who also had type 2 diabetes and ceased to be diabetic after FGF-1 treatment. In our medical research study on type 2 diabetes currently being conducted in Las Vegas, we have dosed over 65 people, and the results are very promising.

I would have said no if you had asked me in December 2025, "Can FGF-1 heal and thereby reverse Type-1 diabetes?" We believe type 2 diabetes is a neurological disease caused when the glucose-sensing neurons in the brain are dysfunctional. Type 1 diabetes results when the beta cells in the pancreas are dysfunctional, and we have no data on that.

A diabetes study out of China was shown to us by a friend, in which Chinese researchers injected FGF-1 into the belly of type 2 diabetics to see if it would reverse the condition. It did not. But what was impressive was that they reported material improvements in liver and pancreas function.

In February 2026, Vika had our type 2 diabetes protocol in Las Vegas revised to offer test subjects, at their option, a shot of FGF-1 in the belly to see if it improved liver and pancreas function. It took Vika 4 days to modify that protocol and get IRB approval. I believe the similar protocol change with the FDA involvement would have taken years. We are now seeing the first data back, and I am starting to think FGF-1 can regenerate the beta cells in the pancreas and possibly reverse type 1 diabetes.

Discovery is finding something you did not know.

Why Zhittya Won't Spend Money It Doesn't Have

Back to kidney disease: it is the 8th or 9th leading cause of death in the United States, with an estimated 35 million American sufferers. And kidney disease is not in the top 20 diseases Zhittya is addressing right now. Heart disease, stroke, type 2 diabetes, diabetic foot ulcers, Parkinson's disease, traumatic brain injuries, and more — Zhittya is busy.

Zhittya's management operates in the real world. You do not spend money you do not have.

I have been lectured by biotech executives who raised $400 million for their company and progressed the "traditional way," and who tell me I am wrong. They tell me that I am wrong to say you should not spend money you do not have, and that I am wrong to say that if you cannot see a path to positive cash flow within a reasonable time frame (not 20 years), you should not do it. I have been told I am wrong many times by PhDs with no real-world business experience. When their companies fail and they ask me for a job, it is sad. Many great medical discoveries have not reached sick people because the people running those companies did not understand a basic business reality: you cannot succeed if you run out of money.

Realities of Developing Medical Treatments

This section is going to get me in trouble. If I wanted to avoid trouble, I should have gone to work at the Post Office.

It is reported that since 1985, almost $12 trillion has gone into medical research, roughly $6 trillion in the U.S. and $6 trillion in the rest of the world. All the billions poured into cancer research, heart research, and more have shown very little return to the sick humans they were meant to help, even after 40 years.

Politicians and charity fundraisers talk about all the money going into a project. They talk about the hundreds of billions of dollars going into the schools. They do not talk about the fact that those kids cannot read, write, or do basic math. They ignore the outcomes and just talk about how much money was spent. I love the California high-speed rail line from Los Angeles to San Francisco — it was started 10 years ago, about $14 billion spent so far, and very little track has been laid down. Now they say if they spend only another $200 billion, it might work. Yes, this is government bureaucracy at its finest.

A Medical Example

The Michael J. Fox Foundation's 2024 audited financial statements report contributions of $485,278,102 for that year. They disclose having raised $2.5 billion over the last 20+ years. To my knowledge, the Michael J. Fox Foundation has not shown that a single person in 20 years has improved or benefited from all that money. Mr. Fox himself does not appear to be improving.

Here is a link to one of Zhittya's Parkinson's disease patients, Mark Davis: https://www.youtube.com/watch?v=UCaHvglxGQc

In May 2023, Mark was in a wheelchair and could not lift his foot. He was in worse shape three years ago than Michael J. Fox is today. Yet you can see him two years later walking by himself, and six months after that, playing catch with a ball (demonstrating eye-hand coordination). Zhittya has many Parkinson's patients who have not declined like Michael J. Fox—our results show that they are improving.

Zhittya has never taken a penny of donations. Zhittya has never taken a penny of government grants. Despite this, Zhittya is delivering results. Real results to real people.

Question: Instead of people giving the Michael J. Fox Foundation $485 million in one year, with no patient improvements to show for it, why not invest $5 million in a Zhittya Medical Research Study with Zhittya to gather more data on FGF-1 and treat an additional 100 sick Parkinson's patients? That would accelerate the data needed for FDA clinical studies and, I hope, FDA approval, so the Parkinson’s disease public of millions of people could be treated.

Why Zhittya Delivers Results

Many of you already know that I was a professor at several universities. What you may not know is that since the mid-1970s, I have been speaking on free market economics all over the world: Tokyo, Seoul, Taipei, Singapore, Kuwait, Dubai, Lagos, Kyiv, Belgrade, London, and many more places.

I believe free market economics always provides better lives for the people who live in those societies. Expert-led planned economies such as socialism, communism, and central planning always fail.

I was asked to go to Eastern Europe and help countries switch to free market economics. Then I went to African nations, followed by the former Soviet Union, and then to Asia. As a fanatic free-market person who hated communism, when I first went to the Soviet Union in the 1980s (before communism fell), I came back and reported, "The communist Soviet Union has one of the greatest free-market economies in the world!"

Friends thought I was crazy. I explained that the government shops have nothing, the money is worthless, and everyone knows it, but in the black market, you can get anything. Food, gas, clothes—everything was there because free market entrepreneurs made it happen, despite government obstacles. People are brilliant, and they will create solutions to problems from their own personal genius. When the government food stores in Kyiv had only empty shelves, you could walk to an open bazaar with people from Georgia, Armenia, and elsewhere who had food for sale. The human genius of self-enlightenment works everywhere.

Two Economic Models

Expert-led economies: Very intelligent people come up with a plan. It sounds great, and other intelligent people support it and finance it, often with other people's money (not their own). When something goes wrong (and something always goes wrong—that is reality), no one takes responsibility for resolving the problems. They hide from the problems (they hide because they can), and that is the worst thing you can do. An unresolved problem only gets worse.

Entrepreneur-led economies: Entrepreneurs know they must provide customers with a better product and service than the competition, or they will fail. A high school graduate in Missouri who decides to start a construction company knows he must build a product people want, in the way they want it, at a value that causes people to voluntarily transfer their money to him for his product or services.

Here is the important part: that person cannot hide from the problems. He must deal with them, or he fails. He risks his money, his energy, his dreams, his reputation, the future of his family, and more. He must succeed, or he fails. And he cannot hide from the problems that always occur. Free markets succeed because you can NOT HIDE from the problems.

Every day at Zhittya, we are confronted with problems that we have to deal with. Some problems are resolved with great news: maybe FGF-1 can heal type-1 diabetes! Some problems are practical: Can we deliver FGF-1 up the nose better? Some are heartbreaking, as when a mother comes to us asking: “Can FGF-1 treat my child? My child is suffering.” When you believe the answer is yes, but you cannot help them right now because you are swamped, it is a lousy feeling.

The smartest economics PhD in Moscow could not figure out how to get food from Ukraine to the people in Moscow. An uneducated Ukrainian farmer growing crops on a hidden plot of land grew the food and got it delivered to the Moscow bazaars and would accept payment only in German marks. He could not hide from his problems. He had to deal with them, and he had to succeed.

Zhittya has over a hundred medical indications in front of us that we cannot process right now. Kidney disease alone could be a multi-billion-dollar opportunity, treating 36 million Americans and perhaps 600 million people worldwide, and yet it is not on our Top Ten list. The reason is that we are processing the medical indications where we already have:

1. Animal data
2. Human data

3. Safety results Zhittya has that data for type 2 diabetes, heart disease, brain vascular disorders, chronic wounds, and more. Zhittya must take the medical indications with the best human data and work to get those approved for sale first. Funding Status for Zhittya's Medical Research Studies A Brief History of Medical Research Studies Before modern medicine, schools of medicine existed all over the world. The University of al-Qarawiyyin, founded in 859 CE in Fez, Morocco, is one example.

Medical discovery and proper procedures were well known and well-studied. Great medical discoveries occurred through trial and error long before there was an FDA, and millions of lives have been saved by common-sense medical discovery techniques developed over the centuries. Penicillin was discovered and advanced without FDA clearance, and it has saved millions of lives.

In 1964, the world's medical community assembled in Helsinki, Finland, to establish the code for conducting medical research studies. The world agreed to the Helsinki Declaration of 1964. The United States is a signer of that agreement, and most universities in the United States conducting medical research studies today follow its rules.

In the 1980s, biotech medical discovery produced some amazing biological medicines: human growth hormone, erythropoietin, biologically manufactured insulin, and more. These companies needed to pay for clinical studies to obtain U.S. FDA clearance so that those medicines could be sold to sick patients. Many turned to a new financial vehicle called Special Purpose Entities. It is reported that in the 1980s, $1.4 billion USD was raised this way.

Nature Biotechnology wrote an article in March 2004 discussing this method of financing. That article is available for you to read here: zgm.care/invest

If you read the article, please look at page 274, which lists the biotech companies that used Special Purpose Entities to fund their medical studies. Many of those companies did not have the money to proceed in the 1980s—and I believe this form of financing saved them and delivered those medicines to people. Look at that list: many are today's giants of biotechnology, and those investors earned excellent returns.

Why Zhittya Is Using This 1980s Method Now

I will use Zhittya's type 2 diabetes program as an example. Zhittya has effectively completed the $5 million funding for the medical research study to treat 100 type-2 diabetic patients in Las Vegas, so I can talk about that study without a conflict of interest.

• We have 12 years of animal data showing FGF-1 reverses type 2 diabetes.
• In our human Parkinson's disease studies, we witnessed 25 people who also were type 2 diabetics, and who ceased to be diabetic after FGF-1 treatment.
• 37 million Americans have type 2 diabetes. It is reported to cost $12,000– $18,000 per year per patient for their medical care and that the disease will shorten a patient's life by 6 to 10 years.

If one round of intranasal FGF-1 dosing reverses type 2 diabetes, that is a wonderful improvement in human life. Zhittya believes it can offer this treatment for about 20% of the current 4-year cost of treating that disease, saving hundreds of billions of dollars for payors, insurance companies, and governments and enhancing the lives of tens of millions of people.

Zhittya is operating on a positive cash flow today. Any businessperson will tell you that positive cash flow is better than negative cash flow. Negative cash flow describes 90% of all developmental biotech companies today, which is why the failure rate is 95%. I believe Zhittya, from its present operations, can earn an extra $5 million over the next two years and thereby fund the type 2 diabetes study to obtain the medical data we need to advance to the FDA. Questions need to be answered, like: What is the best dosing? How long should you dose? How long does the type 2 reversal last? Does it last for 4 years, 8 years, 20 years, or forever? We do not know these answers yet, and before we go to the FDA and spend tens of millions of dollars, we should.

I will not jeopardize Zhittya's financial existence today by spending money we do not have. So Zhittya could wait two or five years to get around to developing a type 2 diabetes treatment. But the business opportunity is massive. If FDA- approved and covered by medical insurance, my guess is the business opportunity potential exceeds $100 billion worldwide.

Looking back to the 1980s and the $1.4 billion raised through Special Purpose Entities, I estimate in today's money that would be around $3 billion. We put together a package, and from our existing shareholders and friends, we gathered the $5 million to fund the diabetes project. Zhittya is now conducting a 100- person type 2 diabetes medical research study in Las Vegas, in 100% compliance with the Helsinki Declaration, proper medical study practices, and Nevada state rules. We are learning a lot, and I believe this data will set the path for Zhittya to obtain approval to sell our FGF-1 medicine to reverse type 2 diabetes sooner, by many years. Sooner means less suffering and fewer deaths.

Yes, Zhittya has signed contracts with investors agreeing that Zhittya will pay them 50% of the cash revenues from Zhittya’s future FGF-1 sales for type-2 diabetes until those investors have received 10 times what they invested. As a backup and a sign of our belief, Zhittya has also given those investors a Put Option: at 48 months, if they are not happy for any reason, Zhittya will buy their investment back for 2 times what they invested, less any money they have already received.

The basic math is simple: for $5 million now, Zhittya will pay $50 million in the future from sales of the approved medicine. Question: If I believe the potential is $100 billion, why would I not pay $50 million to capture it 2 or 5 years sooner? Two Additional Medical Research Fundings Underway 1.

No-Option Heart Disease

Heart disease is the leading cause of death in the world.

Zhittya and the Bahamas Heart Centre are conducting a 100-person medical research study to treat no-option heart disease patients with FGF-1, building on three prior successful heart studies. Zhittya is raising $10 million USD to fund this study.

In treating heart disease, we have seen 100% success with zero adverse events across the last 30 years, and I believe the millions of people facing certain death will travel to the Bahamas to save and extend their lives.

If you are interested in learning more about the investment opportunity for the “Small Vessel Heart Disease Medical Research Study” (minimum investment of $25,000), please email me at Dan333@aol.com or call 702-802-8373. Investment benefits include:

• 50% royalty on Zhittya's revenue for the treatment of small vessel heart disease (up to 10x the original investment).
• Put Option: Receive 2x your original investment after 48 months if you are not happy.

I believe the demand among well-resourced patients to save their own lives will be strong. If heart disease runs in your family, you may be able to invest, earn returns, and benefit your own health and life—and advance medical innovation that could help millions. 2. Chronic Wounds—Diabetic Foot Ulcers (DFUs)

In October 2025, Zhittya announced it would raise $5 million for a Medical Research Study for chronic wounds. Zhittya raised $1 million in a few weeks (out of the $5 million target) for the chronic wounds medical research study. That first million allowed us to move forward and identify an enhanced path to success that I believe will be quicker and more successful. The interest from investors was strong, and what surprised us even more was what happened next: as word got out about what we were doing, companies that conduct animal studies and Phase I and II clinical studies in the wound healing arena came knocking at our door asking for the business.

It seems the billions of dollars that poured into biotech during the pandemic boom era have now disappeared. In 2025, the new FDA management is saying that less animal testing should be done. The result is that roughly 600 biotech companies failed each year in 2022, 2023, 2024, and 2025, because no venture capitalist will invest; they are no longer hot for COVID-era biotech. We received quotes for tasks at amazingly low prices. Not only were the prices low, but the vendors could start immediately and finish quickly, as we would not be waiting in line behind a thousand biotech companies that no longer exist. We have decided to take advantage of this cost-savings window and get wound healing IND applications submitted for Phase I as fast as possible.

For those worried about us: I do not have survivor's guilt that Zhittya survived when thousands of biotech companies failed. We fought and sacrificed to get Zhittya through the storm, and some smooth sailing has been earned by the team.

Now we are pushing to get more capital (remaining open $4 million) into the Wound Healing Medical Research Study for diabetic foot ulcers, because I believe we could be at the FDA in early 2027.

For more information on the DFU program, go to: cure-wounds.com

If you are interested in the Wound Healing investment opportunity (minimum investment of $25,000), email me at Dan333@aol.com or call 702-802-8373. It has the same benefits structure as mentioned above:

• 50% royalty on Zhittya's revenue for wound healing treatments (up to 10x the original investment).
• Put Option: 2x your original investment after 48 months if you are not happy.

White Paper: Post-Concussion Syndrome

Over 2 million people per year suffer from a condition known as Post-Concussion Syndrome (PCS). Our new neurology scientific consultant, an expert in brain trauma and PCS, has written a white paper on this topic because he believes FGF- 1 could be a treatment for this unmet medical need. The white paper will be available soon.

Vika's Section Patient Messages

#1) Brett Favre — Pro Football Hall of Famer, and Zhittya Parkinson's patient posted on X (formerly Twitter) May 11, 2026.

"A few months ago I met Dan Montano, the CEO of Zhittya, Inc. They have treated me twice intranasally with the biologic FGF-1 to enhance blood flow to my brain. I had no side effects, and I'm happy to say I've been able to significantly reduce my dopamine medication levels.

Folks don't realize how much small blood vessel damage is associated with so many neurodegenerative diseases — not just stroke.

Dan and his team are also having a lot of success with Type-2 diabetes, and are beginning treatment protocols for Multiple Sclerosis, stroke, and Post-Concussion Syndrome. I am looking forward to many more treatments for my Parkinson's. Thx Dan!"

Read his post here and see the picture below: https://x.com/BrettFavre/status/2053880774252757487

On the left, Vika. On the right, Brett Favre.

#2) Hi Vika, I trust that you and Dan are doing well. Just thought that I would let you know that V went to the neurologist for her check up and the neurologist is amazed that V is doing so well considering the fact she has had Parkinson’s for the last 14 years and the neurologist thinks that this most probably due to the FGF-1 treatment. Patients with Parkinson’s for this period of time are usually in really bad shape.

So we live in hope that with the new FGF-1 protocols, V will continue to improve over time.

#3) Dear Vika: One of the reasons I am anxious to start back up is both GP commented unsolicited that my speech had improved and she did not know I was doing this pilot. My neurologist commented that my symptoms did not worsen which is a first.

Phil

#4) Good afternoon Vika, I have a question for you regarding the FGF. Is what I received the same strength as before? The reason I ask is because I feel different after my second dose! It is slight but I do feel better kinda hard to describe but it is noticeable and I am currently not on any Parkinson’s meds __________________________________________________ Cross-Border Medical Tourism Cross-Border Medical Tourism services are for people who want to be considered for Zhittya's future clinical trials or current medical research studies. Cross-Border is now arranging medical tourism to treat Parkinson's disease in Las Vegas, which began in January 2026.

Cross-Border is working on filling the Las Vegas medical research studies (intranasal FGF-1 for Parkinson's disease, type-2 diabetes, and more) on the following dates:

Cohort #47: May 25 – 28, 2026

Cohort #48: June 23 – 25, 2026

Cohort #49: July 27 – 29, 2026

Cohort #50: August 24 – 26, 2026

Cohort #51: Sept 28 – 30, 2026 To be considered for a cohort, please contact Sam Cross at Cross-Border Medical:

• Email: Sam.crossbordermedical@gmail.com
• Phone: 714-393-8605 If you are also interested in participating in a functional MRI brain scan study at Washington University in St. Louis, please let Sam know. There are a finite number of imaging slots. These studies will examine brain blood flow before and after FGF-1 treatment. Upcoming Events July 9–11: FreedomFest, Las Vegas, NV Caesars Palace, Paradise, Nevada Zhittya will be making a main stage presentation on Zhittya's medicines.

July 10, 2026: Zhittya is sponsoring a dinner on "Freedom to Try Medical Innovations." I hope we will have 500 hundred attendees, and I will be presenting on Medical Breakthroughs resulting from the Freedom to Try. We also hope to have a noted VIP guest speaker addressing this important topic.

FreedomFest ticket link: http://freedomfest.swoogo.com/zhittya2026

July 20–22: MoneyShow Las Vegas Caesars Palace, Paradise, Nevada

Topic: Breakthrough biotech medicine for treating the cause of death of 65% of all adults.

July 22–25: Caribbean Cardiac Society 39th Annual Cardiology Conference Atlantis, Paradise Island, Bahamas

Zhittya will present on its heart medicine for treating small vessel heart disease. Last year, this conference had about 350 attendees from around the world. It is my hope that we can enlighten hundreds of cardiologists about a new treatment option for their no-option heart patients.

August 26–28: MoneyShow San Francisco Fairmont Hotel, San Francisco, California

Topic: Breakthrough biotech medicine for treating the cause of death of 65% of all adults. Conclusion:

In May 2022, Dr. Jacobs and I were in the British Virgin Islands dosing Becky Parker and Dr. Daniel Clark, our first volunteers to be treated with FGF-1 for their Parkinson’s disease. This May starts the 4th year of our journey to recovery from Parkinson’s disease. We have dosed over 250 people, with no safety issues and, I believe, very impressive improvements.

I can easily reflect now on what I had anticipated then and realize how foolish I was. Everything has taken longer, cost more, and been very exhausting. We have explained our medical indications for the brain applications, and I see progress. Tens of millions of people suffer from disrupted blood flow in their brains, and I believe FGF-1 can rejuvenate their brains and give them a better life.

Getting to meet Brett Favre has been very motivating. He is a champion. He played injured and won. He did not quit; he did what had to be done to win. Now he is part of our team, and I look at him and realize Zhittya and its over 250 Parkinson’s team members will also win, because none of us will quit.

I am horrible at dealing with delays. God gave me an impatience that is a strong part of me. Zhittya has come a long way, and I believe we have pending medical breakthroughs for heart disease, brain disorders, diabetes, diabetic foot ulcers, and more. I expressed my frustration to a dear friend, who replied, “Dan, you have been working on the heart disease treatment for 28 years; most people would have given up a long time ago. You are just not smart enough to know when to quit. When you succeed and millions of people’s lives are extended, it will not be because you were smart; it will be because you do not know how to quit!”

One last comment: a friend of mine of over 30 years, invested $50,000 in the Zhittya type 2 diabetes Medical Research Study. He is in his 80s and has been very successful. He told me the $50,000 he invested in trying to reverse type 2 diabetes brings him more happiness, than the millions he has given to traditional medical charities. He has seen so much benefit that he has even recommended us to multiple type 2 diabetic patients who have seen fantastic results thus far. He likes seeing real progress and success that Zhittya is having with his money. He loves telling people he is funding a medical study to see if we can cure their diabetes now! He said to me, “For the first time he can feel his money is making a difference!” That is Zhittya, we are making a difference NOW!

I thank all of you for your involvement, prayers, and guidance. My father was a hard man. There was Right and there was Wrong. He told my older brother and me, “If the task was easy, God would have given it to someone else. He saves his most difficult task for those he has prepared the most.”

I am blessed!

God bless you, and thank you all.

Dan Montano CEO, Zhittya Genesis Medicine 8683 W. Sahara Ave., Suite 280 Las Vegas, NV 89117 (USA) 702-802-8373 zgm.care

<https://x.com/BrettFavre/status/2053880774252757487>

<https://www.youtube.com/watch?v=UCaHvglxGQc>

<https://zgm.care/invest>

<https://cure-wounds.com/>

<https://x.com/BrettFavre/status/2053880774252757487>

<http://freedomfest.swoogo.com/zhittya2026>

<https://zgm.care/>